Caris Assure Blood Based Profiling
Less Invasive, More Intelligent Than Ever
Be Sure with Caris Assure
With deep molecular insights from a simple blood sample, Caris Assure™ offers a minimally-invasive option for biomarker analysis and serial monitoring of cancer patients when tissue samples are not available. No matter the specimen type – tissue or blood – Caris Life Sciences’ flexible, multi-faceted molecular profiling platforms deliver uncompromising reliability to guide personalized treatment decisions and improve patient outcomes.*
The Most Powerful Liquid Biopsy Assay Ever Developed.
Novel cNAS Approach
Circulating Nucleic Acid Sequencing
(cfDNA, cfRNA, gDNA, gRNA)
Whole Exome Sequencing (WES) DNA
SNV INDEL CNA
Whole Transcriptome Sequencing (WTS) RNA
Fusion Variant Transcript
22,000 Gene Coverage
Somatic Tumor Somatic CHIP
Germline†
Genomic Signatures
MSI TMB LOH
Result Rate
>99%
Whole Exome and Whole Transcriptome Sequencing from Blood
Caris Assure analyzes all 22,000 genes at the DNA and RNA level using whole exome and whole transcriptome sequencing, providing the most robust and accurate assessment of the key molecular features of a patient’s cancer. This comprehensive approach identifies all pan-cancer biomarkers, including a wide range of variant types and genomic signatures. This powerful assay includes characterization of somatic tumor alterations, somatic CHIP alterations and identification of incidental germline findings. The assay further enables minimally invasive serial monitoring for detection of tumor heterogeneity and emergence of resistance mutations. The assay is intended for patients with previously diagnosed solid tumors.
Accurate, Actionable Results for More Patients
Circulating Nucleic Acids Sequencing (cNAS) is a novel liquid biopsy molecular profiling approach that analyzes circulating cell-free DNA and RNA (cfDNA, cfRNA) plus genomic DNA and RNA (gDNA, gRNA) from circulating white blood cells. DNA-only molecular profiling assays often do not provide enough nucleic acid material for sequencing due to low- or non-shedding tumors. With more information-rich nucleic acids to analyze, Caris’ novel cNAS assay addresses the non-shedding issue, generating an actionable result for more patients while improving sensitivity and specificity.Looking for a Specific Gene?
Use our full gene search to verify that it is included in Caris profiling, or browse the list of genes most commonly associated with cancer.
Coming Soon in 2022!
Caris Assure blood-based profiling will be available in summer/fall of 2022, with expanded availability in 2023. Not available in all locations.
The online form below is intended for healthcare professionals only. Sign up to get updates on Caris Assure features and availability. If you are a patient, please contact your doctor for more information about Caris Assure.
* Caris Assure is intended for patients with previously diagnosed solid malignant neoplasms where tissue is not available, or the diagnostic specimen has been exhausted, and is to be used by qualified healthcare professionals. Subject to availability. Not available in all locations.
† Not a replacement for comprehensive germline testing. Incidental pathogenic alterations detected in ACMG recognized cancer genes are reported. Negative results do not imply the patient does not harbor a germline mutation.